Cerebrolysin

This article may be expanded with text translated from the corresponding article in Russian. (July 2019) Click [show] for important translation instructions. Machine translation like DeepL or Google Translate is a useful starting point for translations, but translators must revise errors as necessary and confirm that the translation is accurate, rather than simply copy-pasting machine-translated text into the English Wikipedia. Consider adding a topic to this template: there are already 2,212 articles in the main category, and specifying|topic= will aid in categorization. Do not translate text that appears unreliable or low-quality. If possible, verify the text with references provided in the foreign-language article. You must provide copyright attribution in the edit summary accompanying your translation by providing an interlanguage link to the source of your translation. A model attribution edit summary is Content in this edit is translated from the existing Russian Wikipedia article at [[:ru:]]; see its history for attribution. You should also add the template {{Translated page}} to the talk page. For more guidance, see Wikipedia:Translation.

Cerebrolysin

Vial of the product
Clinical data
Other names	FPF-1070
Identifiers
CAS Number	12656-61-0
DrugBank	16599
UNII	37KZM6S21G

Cerebrolysin (developmental code name FPF-1070) is a mixture of enzymatically treated peptides derived from pig brain whose constituents can include brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), nerve growth factor (NGF), and ciliary neurotrophic factor (CNTF).

Cerebrolysin has also been studied for potential use with a wide variety of neurodegenerative disorders, though research is preliminary.^[1] Cochrane reviews suggest no benefit in the treatment of acute stroke and an increased rate of spontaneous adverse events requiring hospitalization.^[2] Conversely, reviews suggest positive effect when cerebrolysin is used with vascular dementia.^[3] All Cochrane analysis to date stresses that these relationships needed to be confirmed by further high quality clinical trials.

Medical uses[]

Stroke[]

Reviews suggest no benefit for treatment of acute ischemic stroke with cerebrolysin, though they also emphasize the need for further high quality studies. In addition, cerebrolysin use was associated with a higher rate of spontaneous adverse events requiring hospitalization.^[2] Studies of ischemic stroke in Asian subpopulations also found an absence of benefit.^[4]

An early study also suggested a lack of benefit with hemorrhagic stroke related to cerebral aneurysm.^[5]

Dementia[]

Reviews suggest an improvement in cognitive function with cerebrolysin use for vascular dementia, though as with studies on stroke, further high quality research is needed.^[3]

Adverse effects[]

In trials studying the use of cerebrolysin after acute stroke, there was an increased risk of "serious adverse events" requiring hospitalization. These were specifically defined as:

"...any untoward medical occurrence that, at any dose, resulted in death, [was] life‐threatening, required inpatient hospitalisation or resulted in prolongation of existing hospitalisation, resulted in persistent or significant disability/incapacity, [was] a congenital anomaly/birth defect, or [was] a medically important event or reaction”.^[2]

Mechanism of action[]

In vitro and animal studies suggest neurotrophic effects of cerebrolysin similar to endogenous neurotrophic factors, though its specific molecular pharmacodynamics are not clear.^[6] Studies of dementia suggest decreased beta-amyloid deposition.^[7]

History[]

The preparation was allegedly first created in 1949 by Gerhart Harrer, an Austrian professor at the University of Innsbruck.^{[citation needed]}

Cerebrolysin is widely used in Russia, Eastern Europe, China, and other post-Soviet and Asian countries.^[2] It has been included on the list of Vital and Essential Medicines (ЖНВЛС) in Russia since 1992.^[8]

Cerebrolysin is not a scheduled drug in the United States.^[9][10]

Research[]

Early studies have suggested potential use of cerebrolysin with a wide variety of neurodegenerative disorders, including traumatic brain injury,^[11][12] schizophrenia,^[13] multiple sclerosis,^[14] cerebral palsy^[15] and spinal cord injury^[16][17] though research is still preliminary.

References[]